At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 3 enrolled
Drug / intervention
AKCEA-ANGPTL3-LRxdrug
Likely dose
AKCEA-ANGPTL3-LRx 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRx (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
In Brief
A Phase 2 clinical trial evaluating AKCEA-ANGPTL3-LRx for Familial Chylomicronemia Syndrome and 2 related conditions. Completed, enrolled 3 participants across 1 site.
Detailed Summary
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFamilial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
CountriesCanada
CollaboratorsIonis Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartDec 2017
Primary CompletionJun 2018
Study CompletionSep 2018
TodayJul 2026
First PostedDec 4, 2017
Enrollment StartDec 21, 2017
Primary CompletionJun 12, 2018
Study CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.6 years ago
Interventions
AKCEA-ANGPTL3-LRxdrug
AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.